View in EDS HTML Full Text PDF Full Text

Early versus escalation treatment of tocilizumab in neuromyelitis optica spectrum disorder: a retrospective study.

Saved in:
Bibliographic Details
Title: Early versus escalation treatment of tocilizumab in neuromyelitis optica spectrum disorder: a retrospective study.
Authors: Qi, Yuan (AUTHOR), Liu, Rongrong (AUTHOR), Zhao, Yuexin (AUTHOR), Zhang, Linjie (AUTHOR), Zhang, Qiuxia (AUTHOR), Li, Limin (AUTHOR), Yang, Chunsheng (AUTHOR), Yang, Li (AUTHOR), Jiang, Wei (AUTHOR)
Source: Neurological Sciences. Jun2025, Vol. 46 Issue 6, p2759-2764. 6p.
Subjects: Neuromyelitis optica, Medical sciences, Tocilizumab, Rituximab
Abstract: Background: Tocilizumab is effective in neuromyelitis optica spectrum disorder (NMOSD). It remains unclear when to initiate or discontinue tocilizumab treatment. We aimed to compare the efficacy of early versus escalation tocilizumab treatment in patients with NMOSD. Methods: A retrospective study of 41 patients with NMOSD who received regular tocilizumab administration was conducted. The early tocilizumab group comprised patients who started tocilizumab after their first attack, while the escalation group included patients who initially received empirical disease-modifying drugs (DMDs) and later escalated to tocilizumab after relapses. Tocilizumab was administered at 8 mg/kg with routine infusions at 4-week intervals. The primary outcome was improvement in the extended disability status scale (EDSS) score at months 3, 6, and 12 during the follow-ups. An additional secondary outcome was annualised relapse rate (ARR). Results: The early tocilizumab treatment group showed reduced median EDSS scores at 3, 6 months, with no further reduction at 12 months. The escalation treatment group showed reduced EDSS score at 6 months, with no further reduction at 12 months. The Inter-group analysis showed the early tocilizumab treatment group had significantly lower EDSS scores at 3, 6, and 12 months compared to the escalation treatment group. The ARR was not different at 36 months. Additionally, no difference of ARR was observed in those who were transferred to low-dose rituximab. Conclusions: Early use of tocilizumab reduces the degree of disability compared to escalation treatment in NMOSD, with no much differences on relapse rate. Low-dose rituximab may be a feasible candidate switching from tocilizumab. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 185240199
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Early versus escalation treatment of tocilizumab in neuromyelitis optica spectrum disorder: a retrospective study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Qi%2C+Yuan%22">Qi, Yuan</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liu%2C+Rongrong%22">Liu, Rongrong</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhao%2C+Yuexin%22">Zhao, Yuexin</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhang%2C+Linjie%22">Zhang, Linjie</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhang%2C+Qiuxia%22">Zhang, Qiuxia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+Limin%22">Li, Limin</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yang%2C+Chunsheng%22">Yang, Chunsheng</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yang%2C+Li%22">Yang, Li</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jiang%2C+Wei%22">Jiang, Wei</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. Jun2025, Vol. 46 Issue 6, p2759-2764. 6p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Neuromyelitis+optica%22">Neuromyelitis optica</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+sciences%22">Medical sciences</searchLink><br /><searchLink fieldCode="DE" term="%22Tocilizumab%22">Tocilizumab</searchLink><br /><searchLink fieldCode="DE" term="%22Rituximab%22">Rituximab</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: Tocilizumab is effective in neuromyelitis optica spectrum disorder (NMOSD). It remains unclear when to initiate or discontinue tocilizumab treatment. We aimed to compare the efficacy of early versus escalation tocilizumab treatment in patients with NMOSD. Methods: A retrospective study of 41 patients with NMOSD who received regular tocilizumab administration was conducted. The early tocilizumab group comprised patients who started tocilizumab after their first attack, while the escalation group included patients who initially received empirical disease-modifying drugs (DMDs) and later escalated to tocilizumab after relapses. Tocilizumab was administered at 8 mg/kg with routine infusions at 4-week intervals. The primary outcome was improvement in the extended disability status scale (EDSS) score at months 3, 6, and 12 during the follow-ups. An additional secondary outcome was annualised relapse rate (ARR). Results: The early tocilizumab treatment group showed reduced median EDSS scores at 3, 6 months, with no further reduction at 12 months. The escalation treatment group showed reduced EDSS score at 6 months, with no further reduction at 12 months. The Inter-group analysis showed the early tocilizumab treatment group had significantly lower EDSS scores at 3, 6, and 12 months compared to the escalation treatment group. The ARR was not different at 36 months. Additionally, no difference of ARR was observed in those who were transferred to low-dose rituximab. Conclusions: Early use of tocilizumab reduces the degree of disability compared to escalation treatment in NMOSD, with no much differences on relapse rate. Low-dose rituximab may be a feasible candidate switching from tocilizumab. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=185240199
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10072-025-08046-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 6
        StartPage: 2759
    Subjects:
      – SubjectFull: Neuromyelitis optica
        Type: general
      – SubjectFull: Medical sciences
        Type: general
      – SubjectFull: Tocilizumab
        Type: general
      – SubjectFull: Rituximab
        Type: general
    Titles:
      – TitleFull: Early versus escalation treatment of tocilizumab in neuromyelitis optica spectrum disorder: a retrospective study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Qi, Yuan
      – PersonEntity:
          Name:
            NameFull: Liu, Rongrong
      – PersonEntity:
          Name:
            NameFull: Zhao, Yuexin
      – PersonEntity:
          Name:
            NameFull: Zhang, Linjie
      – PersonEntity:
          Name:
            NameFull: Zhang, Qiuxia
      – PersonEntity:
          Name:
            NameFull: Li, Limin
      – PersonEntity:
          Name:
            NameFull: Yang, Chunsheng
      – PersonEntity:
          Name:
            NameFull: Yang, Li
      – PersonEntity:
          Name:
            NameFull: Jiang, Wei
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: Jun2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 15901874
          Numbering:
            – Type: volume
              Value: 46
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Neurological Sciences
              Type: main
ResultId 1